Shanghai launches plan to spur R&D in biomedicine

en.china-shftz.gov.cn | Updated:Jul 7, 2021

East China's Shanghai released an action plan to simplify customs \r\nclearance procedures for companies involved in the research and \r\ndevelopment of biomedicine on June 30, which is another effort by the \r\ncity to transform itself into a hub of biomedical innovation.

The \r\nplan, which was issued by five local government departments, including \r\nthe Shanghai Municipal Commission of Commerce and Shanghai customs, \r\nstated that Shanghai will establish a whitelist of biomedical companies \r\nand items used in their research that can be imported to China without \r\nthe need for a clearance form.

According to the plan, biomedical \r\ncompanies and research entities must apply to the local authorities and \r\nprovide a list of items to be imported for R&D purposes until they \r\nare eligible to benefit from the new policy. Applicants must also have \r\nsufficient technology and experience in biomedical research, as well as \r\nan information management system for imported properties.

The \r\nwhitelist is scheduled to be adjusted every six months, and Shanghai's \r\nPudong New Area and Lin-gang Special Area will be the first to launch \r\ntrials after the plan takes effect on Aug 1.

copyright © Shanghai Municipal Commission of Commerce. All rights reserved. Presented by China Daily. 沪ICP备2021016245号-2